Market overview
The global urology ablation devices market is worth USD 1.1 bn in 2026 and is forecast to reach USD 2.8 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Cryoablation, HIFU and focused energy is the largest by technology segment.
| Scope | Devices and single-use kits that destroy prostate, kidney and bladder tissue with heat, cold, water jet, laser or focused ultrasound, used in minimally invasive treatment of BPH and urologic tumours. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 950 mn |
| Value 2026 | USD 1.1 bn |
| Value 2036 | USD 2.8 bn |
| CAGR 2026-2036 | 10.0% |
| Volume 2026 | 434,627 procedures |
| Volume 2036 | 1,072,464 procedures |
| Average price 2026 | USD 2,448 per procedure |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Urology Ablation Devices market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 1.1 bn |
| 2027 | USD 1.2 bn |
| 2028 | USD 1.3 bn |
| 2029 | USD 1.4 bn |
| 2030 | USD 1.6 bn |
| 2031 | USD 1.7 bn |
| 2032 | USD 1.9 bn |
| 2033 | USD 2.1 bn |
| 2034 | USD 2.3 bn |
| 2035 | USD 2.5 bn |
| 2036 | USD 2.8 bn |
Urology Ablation Devices market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Water vapour thermal ablation | 24.0% | 15.2% | USD 255 mn | 5.1% |
| Aquablation | 26.0% | 47.7% | USD 277 mn | 16.9% |
| Laser ablation and enucleation | 18.0% | 10.4% | USD 192 mn | 4.1% |
| Cryoablation, HIFU and focused energy | 32.0% | 26.7% | USD 340 mn | 8.0% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Benign prostatic hyperplasia | 68.0% | 65.3% | USD 724 mn | 9.6% |
| Prostate cancer focal therapy | 16.0% | 21.9% | USD 170 mn | 13.5% |
| Kidney and bladder tumours | 16.0% | 12.8% | USD 170 mn | 7.6% |
By energy
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Thermal | 44.0% | 40.0% | USD 468 mn | 9.0% |
| Cryogenic | 22.0% | 20.0% | USD 234 mn | 9.0% |
| Ultrasound focused | 14.0% | 18.0% | USD 149 mn | 12.8% |
| Laser | 20.0% | 22.0% | USD 213 mn | 11.1% |
By access
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Transurethral | 60.0% | 58.0% | USD 638 mn | 9.6% |
| Transperineal | 26.0% | 30.0% | USD 277 mn | 11.6% |
| Percutaneous | 14.0% | 12.0% | USD 149 mn | 8.3% |
By setting
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 60.0% | 56.0% | USD 638 mn | 9.2% |
| Ambulatory surgery centres | 28.0% | 30.0% | USD 298 mn | 10.8% |
| Urology clinics | 12.0% | 14.0% | USD 128 mn | 11.7% |
Top 25 countries for urology ablation devices by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 88.0% of 2026 revenue and the 25 countries below together hold 96.4%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 553 mn | 52.0% | USD 1.5 bn | 10.1% |
| 2 | China | USD 64 mn | 6.0% | USD 240 mn | 14.2% |
| 3 | Germany | USD 64 mn | 6.0% | USD 141 mn | 8.2% |
| 4 | Japan | USD 64 mn | 6.0% | USD 141 mn | 8.2% |
| 5 | United Kingdom | USD 43 mn | 4.0% | USD 102 mn | 9.2% |
| 6 | France | USD 43 mn | 4.0% | USD 94 mn | 8.2% |
| 7 | Italy | USD 32 mn | 3.0% | USD 69 mn | 8.0% |
| 8 | Spain | USD 27 mn | 2.5% | USD 58 mn | 8.1% |
| 9 | Canada | USD 27 mn | 2.5% | USD 63 mn | 9.1% |
| 10 | South Korea | USD 21 mn | 2.0% | USD 66 mn | 12.0% |
| 11 | Netherlands | USD 20 mn | 1.9% | USD 48 mn | 9.2% |
| 12 | Australia | USD 12 mn | 1.1% | USD 28 mn | 9.2% |
| 13 | Switzerland | USD 8.7 mn | 0.8% | USD 21 mn | 9.2% |
| 14 | Belgium | USD 7.0 mn | 0.7% | USD 17 mn | 9.1% |
| 15 | Sweden | USD 6.0 mn | 0.6% | USD 14 mn | 9.2% |
| 16 | Austria | USD 5.2 mn | 0.5% | USD 12 mn | 9.1% |
| 17 | Turkey | USD 4.6 mn | 0.4% | USD 16 mn | 13.1% |
| 18 | Mexico | USD 4.2 mn | 0.4% | USD 14 mn | 13.2% |
| 19 | Brazil | USD 3.8 mn | 0.4% | USD 13 mn | 13.0% |
| 20 | India | USD 3.5 mn | 0.3% | USD 12 mn | 13.2% |
| 21 | Poland | USD 3.3 mn | 0.3% | USD 11 mn | 13.1% |
| 22 | Taiwan | USD 3.1 mn | 0.3% | USD 7.5 mn | 9.2% |
| 23 | Denmark | USD 2.9 mn | 0.3% | USD 6.9 mn | 9.2% |
| 24 | Saudi Arabia | USD 2.8 mn | 0.3% | USD 9.4 mn | 13.0% |
| 25 | Israel | USD 2.7 mn | 0.2% | USD 8.8 mn | 12.8% |
| Rest of world | USD 38 mn | 3.6% | USD 94 mn | 9.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Boston Scientific
- Olympus
- Teleflex
Group 2: Regional and specialist players
- Procept BioRobotics
- EDAP TMS
- Medtronic
- Lumenis
- AngioDynamics
- HistoSonics
- IceCure Medical
Group 3: Emerging and niche players
- Profound Medical
- SonaCare Medical
- Francis Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the urology ablation devices market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.
The market is divided by technology, by application, by energy, by access, by setting. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the urology ablation devices market?
The global urology ablation devices market is estimated at USD 950 mn in 2025 and USD 1.1 bn in 2026.
How fast will the urology ablation devices market grow?
It is forecast to reach USD 2.8 bn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 1.7 bn.
Which country is the largest market for urology ablation devices?
United States is the largest market by revenue at USD 553 mn in 2026, 52.0% of the global total. The three largest countries together hold 64.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 14.2% a year from 2026 to 2036.
Which urology ablation devices segment is largest?
In the by technology split, Cryoablation, HIFU and focused energy is the largest segment with 32.0% of 2026 revenue.
Who are the leading urology ablation devices companies?
Global leaders include Boston Scientific, Olympus, Teleflex.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Multi-Organ Transplant MonitoringUSD 1.1 bn · 9.0% CAGR
- AmpouleUSD 1.0 bn · 3.6% CAGR
- Hospital Capacity Management SolutionsUSD 1.0 bn · 11.0% CAGR
- Endoscopic Imaging Logistics And ServiceUSD 1.0 bn · 5.5% CAGR
- Catheter-Based Pulmonary Embolism ThrombectomyUSD 1.1 bn · 12.0% CAGR
- Wearable InjectorUSD 1.1 bn · 13.0% CAGR
- Oncology Biomarker Translation ServicesUSD 990 mn · 9.5% CAGR
- Microwave Ablation DevicesUSD 1.2 bn · 9.5% CAGR